Deep Brain Stimulation News and Research

RSS

Deep brain stimulation (DBS) is a surgical procedure used to treat a variety of disabling neurological symptoms—most commonly the debilitating symptoms of Parkinson’s disease (PD), such as tremor, rigidity, stiffness, slowed movement, and walking problems. The procedure is also used to treat essential tremor, a common neurological movement disorder. At present, the procedure is used only for patients whose symptoms cannot be adequately controlled with medications.

Results reported for clinical trial for the treatment of depression using external trigeminal nerve stimulation

Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.

9 May 2012

eTNS therapy can impact symptoms in pharmacoresistant major depression

9 May 2012

DBS may offer hope for patients with mild Alzheimer's

A study on a handful of people with suspected mild Alzheimer's disease (AD) suggests that a device that sends continuous electrical impulses to specific "memory" regions of the brain appears to increase neuronal activity. Results of the study using deep brain stimulation, a therapy already used in some patients with Parkinson's disease and depression, may offer hope for at least some with AD, an intractable disease with no cure.

8 May 2012

Scientists identify first gene associated with congenital asplenia

Researchers at Weill Cornell Medical College and Rockefeller University have identified the first gene to be linked to a rare condition in which babies are born without a spleen, putting those children at risk of dying from infections they cannot defend themselves against. The gene, Nkx2.5, was shown to regulate genesis of the spleen during early development in mice.

4 May 2012

Conference to focus on deep brain stimulation for OCD, depression

Deep brain stimulation, increasingly recognized as an effective therapy for certain cases of Parkinson's disease, dystonia and tremor, also may help patients who suffer from obsessive-compulsive disorder or depression that fails to respond to other treatments.

27 Apr 2012

New article describes design and properties of magnetoelectric composite materials

Up to now, the brain's magnetic field is measurable only under technical laboratory conditions. This technique is therefore not feasible in terms of the broader medical use, although it would be significant for diagnosing numerous conditions such as epilepsy and dementia, or even for improving therapies such as deep brain stimulation for treating Parkinson's disease.

27 Apr 2012

Great Lakes NeuroTechnologies secures funding for development and testing of innovative neurotechnology

Great Lakes NeuroTechnologies Secures Over $4.5 Million in Funding to Fuel New Product Development for Parkinson's Disease and Neuroscience Education April 24, 2012: Valley View, OH - Great Lakes NeuroTechnologies announced today they have secured over $4.5 million is funding for new product development. The funding includes three new projects sponsored by the National Institutes of Health's SBIR program. Each project is focused on developing and testing innovative neurotechnology. Two projects focus on the monitoring and treatment of Parkinson's disease while another will develop a wireless physiological monitor and web-based teaching system for high school neuroscience courses.

26 Apr 2012

Robot assisted laparoscopic radical prostatectomy better than other surgical techniques

Outcomes from use of a robot to assist surgeons in removal of a cancerous prostate are at least as good, if not better, than the other two techniques used for a radical prostatectomy -- open or laparoscopic surgery -- according to a large meta analysis led by researchers at NewYork-Presbyterian/Weill Cornell.

26 Apr 2012

Book aims to improve overall cardiovascular health of its readers

Dr. Antonio M. Gotto Jr., dean emeritus and co-chairman of the board of overseers at Weill Cornell Medical College, is the co-author of a new book called The Living Heart in the 21st Century. The book, a new edition in The Living Heart best-selling series, is the essential resource guide for patients about cardiovascular disease prevention and treatment.

25 Apr 2012

Levodopa-carbidopa intestinal gel better than standard oral form to treat advanced Parkinson's disease

A levodopa-carbidopa intestinal gel (LCIG) works better than standard oral levodopa-carbidopa in reducing "off" time in patients with advanced Parkinson's disease.

18 Apr 2012

Neurosurgeons from NYU Langone to present at AANS annual meeting

Neurosurgeons from NYU Langone Medical Center will present research and discuss surgical approaches and use of new technologies to treat neurosurgical conditions at the annual meeting of the American Association of Neurological Surgeons (AANS), held April 14-18, 2012 in Miami Beach, FL.

16 Apr 2012

Two CNVs may increase risk of aggressive prostate cancer

An international research team led by Weill Cornell Medical College investigators have discovered two inherited-genetic deletions in the human genome linked to development of aggressive prostate cancer.

10 Apr 2012

NINDS awards NeuroSigma Phase I grant to develop TFN-covered stents

NeuroSigma, Inc., a Los Angeles-based medical device company, today announced it has been awarded a Phase I NIH-STTR grant from the National Institute of Neurological Disorders and Stroke (NINDS) for the further development of its Thin-Film Nitinol (TFN)-covered stent for the potential treatment of brain aneurysms.

9 Apr 2012

New NewYork-Presbyterian autism center to open in early 2013

NewYork-Presbyterian Hospital, along with its affiliated medical schools Weill Cornell Medical College and Columbia University College of Physicians and Surgeons, today celebrated the start of construction on the new Center for Autism and the Developing Brain at the Hospital's Westchester campus in White Plains.

5 Apr 2012

Deep brain stimulation has long-lasting effects in patients with severe depression

People with severe depression are constantly despondent, lacking in drive, withdrawn and no longer feel joy. Most suffer from anxiety and the desire to take their own life. Approximately one out of every five people in Germany suffers from depression in the course of his/her life - sometimes resulting in suicide. People with depression are frequently treated with psychotherapy and medication.

5 Apr 2012

Johns Hopkins devises new seizure detection software

Epilepsy affects 50 million people worldwide, but in a third of these cases, medication cannot keep seizures from occurring. One solution is to shoot a short pulse of electricity to the brain to stamp out the seizure just as it begins to erupt. But brain implants designed to do this have run into a stubborn problem: too many false alarms, triggering unneeded treatment. To solve this, Johns Hopkins biomedical engineers have devised new seizure detection software that, in early testing, significantly cuts the number of unneeded pulses of current that an epilepsy patient would receive.

4 Apr 2012

WCMC receives SU2C-PCF Prostate Dream Team Translational Cancer Research Grant

An international team of investigators from centers in the United States and the United Kingdom, including Weill Cornell Medical College, have been awarded a grant for $10 million over a three-year period to study the molecular underpinnings of metastatic prostate cancer while creating a comprehensive testing system to optimize personalized treatments.

2 Apr 2012

Center for Healthcare Informatics and Policy established at Weill Cornell Medical College

Weill Cornell Medical College announced today the establishment of the Center for Healthcare Informatics and Policy (CHiP) to improve health and healthcare through informatics and technology.

31 Mar 2012

New gene transfer technique can treat beta-thalassemia, sickle cell anemia

A team of researchers led by scientists at Weill Cornell Medical College has designed what appears to be a powerful gene therapy strategy that can treat both beta-thalassemia disease and sickle cell anemia. They have also developed a test to predict patient response before treatment.

28 Mar 2012

DBS allows surgeons to control tremors with brain 'pacemaker'

For nearly 30 years, Tom Rogers' left hand would shake when he tried to use it, making even simple tasks such as drinking a glass of water, writing a check, or making a sandwich challenging. The tremor eventually became so disruptive that he lost use of his dominant hand. Rogers sought care and learned that his tremor was a symptom of Parkinson's disease, yet felt he was suffering from something different.

27 Mar 2012